Google’s plan to win the AI health race? Play nice with Apple and other rivals

Google is rolling out a new Google Health app on May 19 with an AI Health Coach powered by Gemini, plus a new Fitbit Air wristband and expanded health-data summaries, weekly fitness plans, and chatbot features. The company also plans to extend AI coaching support to Apple Watch and other devices later this year, broadening its addressable user base beyond Fitbit and Pixel Watch owners. The move strengthens Google’s position in AI-driven consumer health, though it remains a competitive response to OpenAI, Microsoft, Samsung, Oura and Whoop rather than a near-term revenue catalyst.

Analysis

Google is not really selling wearables here; it is trying to own the health-intent layer that sits above devices. That is strategically more valuable than hardware share because it converts a fragmented sensor market into a software distribution problem, where the winner is whoever becomes the default interpreter of data across Apple, Garmin, Oura, and no-device users. The second-order effect is that Google can monetize health engagement without needing to win the wrist, which should compress the moat around smaller app-layer wellness startups and put pricing pressure on premium subscriptions across the category.

The key takeaway for investors is that the monetization path is likely to be slower than the hype cycle. Health advice is a high-frequency use case, but retention will depend on trust, not novelty, and any accuracy headline can quickly reset adoption by weeks or months. In that sense, this is a product-launch catalyst for Google’s AI ecosystem more than an immediate wearables revenue step-up; the real financial upside comes if the app increases Gemini stickiness and lowers churn in Google’s broader paid AI bundle over the next 2-4 quarters.

For Apple, the risk is less direct hardware substitution than gradual disintermediation of the Watch as the primary health interface. If users can keep their preferred device while moving the “coach” relationship to Google, Apple loses some of the service-layer lock-in that justifies premium ecosystem multiples. Garmin is more insulated on enthusiast hardware but could face margin pressure if AI-driven coaching becomes table stakes and simple data display is commoditized; Oura/Whoop are the more vulnerable pure-play software-hardware hybrids because Google is attacking their value proposition at the same price point consumers already pay for coaching subscriptions.

The contrarian view is that markets may be underestimating how difficult health trust is for a general-purpose AI brand. Consumer willingness to ask ChatGPT-style tools about fitness is not the same as willingness to follow them on medical-adjacent recommendations, and regulators or medical institutions can slow the category if adverse-use cases become visible. That argues for treating the announcement as a medium-term optionality event for Google rather than an immediate repricing of wearables or healthcare AI winners.

Key Decisions for Investors

• Long GOOGL vs short a basket of consumer-health app monetizers over 3-6 months; thesis is that Google can use health as a retention wedge for Gemini and Search-adjacent engagement, while standalone wellness apps face feature commoditization.
• Buy GOOGL call spreads dated 6-9 months out to express upside from broader AI app adoption without paying for a near-term wearables re-rating; use strikes above the current implied move because monetization should lag product headlines.
• Short AAPL vs long GOOGL as a relative-value trade for 1-3 months if the market starts pricing 'device-agnostic health coach' as a threat to Apple’s service lock-in; stop if Apple responds with meaningful HealthKit/Apple Intelligence integration.
• Avoid chasing GRMN upside here; this is a sell-the-news catalyst for premium hardware names unless they can prove AI coaching drives higher attach rates. Use any post-announcement strength to fade into strength over days, not months.
• If available, pair long MSFT / short AAPL or neutralize MSFT exposure: Microsoft’s health-AI positioning is less about consumer lock-in and more enterprise/clinical workflows, so it is lower beta to this launch than the headline suggests.